The 340B Drug Pricing Program is an essential source of support for Community Health Centers, allowing them to stretch increasingly scarce federal resources and reinvest in patient care. Health centers report that 340B is integral to their ability to provide high quality, cost-effective care to their patients. This translates to better patient care in any variety of ways, be it through improved pharmacy access, extended health center hours, or the ability to provide additional providers or services.
Recent Hearings & Reports
House Energy and Commerce Committee “Review of the 340B Drug Pricing Program” report, January 2018
Supporting materials for the following hearings below – including witness testimonies, background memo’s, and video recordings – are available on the Energy and Commerce Committee website.
- March 2018 – Senate Health, Education, Labor and Pensions Committee Hearing entitled “Perspectives on the 340B Drug Pricing Program”
- October 2017 – House Energy and Commerce Subcommittee on Oversight and Investigations Hearing entitled “Examining How Covered Entities Utilize the 340B Drug Pricing Program”
- July 2017 – House Energy and Commerce Subcommittee on Oversight and Investigations Hearing entitled “Examining HRSA’s Oversight of the 340B Drug Pricing Program”
NACHC works with a variety of stakeholder organizations to protect and improve the 340B Drug Discount Pricing Program. To learn more about some of this work, please visit the 340B Coalition website.
NACHC Fact Sheets
- NACHC 2018 Policy Paper – 340B
- 2017 Informational Inforgraphic Series: Nuts and Bolts- 340B
- Health Centers and the 340B Drug Discount Pricing Program, June 2014